Literature DB >> 32269062

Morphological change and recovery of corneal endothelial cells after rho-associated protein kinase inhibitor eye-drop (ripasudil 0.4%) instillation.

Yuko Maruyama1,2,3, Yoko Ikeda4,5, Kazuhiko Mori1, Kengo Yoshii6, Morio Ueno1, Haruna Yoshikawa7, Chie Sotozono1, Shigeru Kinoshita8.   

Abstract

BACKGROUND/AIMS: To investigate the time-dependent change of corneal endothelial cell (CEC) morphology and density (CECD) in patients with glaucoma post instillation of rho-associated protein kinase inhibitor ripasudil (Rip) 0.4% eye drops.
METHODS: This observational study involved 163 eyes of 163 patients with glaucoma in whom CEC morphological change was evaluated by CECD calculated via non-contact specular microscopy (NCSM) before and at 1 or 3 months post-Rip instillation. The change of CECD was plotted along with elapsed time from last instillation of Rip. The patients were divided into the following three groups based on the elapsed time post-Rip instillation: Early Group (<2 hours), Middle Group (≥2 hours, yet <6 hours) and Late Group (≥6 hours). The rate of CECD change was then analysed and compared among the three groups. An additional eight eyes of four patients with glaucoma were enrolled for a time-dependent study, with NCSM images evaluated before and at 1, 2, 3, 4 and 6 hours post-Rip instillation.
RESULTS: Morphological changes in the CECs appeared within 1 hour and recovered to normal within 6 hours post instillation. In the Early, Middle and Late Group, the median rate of CECD change as calculated by the NCSM automated software was -5.68%, -4.95% and -0.07%, respectively. The CEC images showed the same morphological changes with observational study in all four cases.
CONCLUSION: Due to transient morphological changes, the NCSM software produced misleading data for determining CECD within 1 hour post-Rip instillation, yet revealed that CEC morphology gradually recovered to normal within 6 hours. © Author(s) (or their employer(s)) 2021. No commercial re-use. See rights and permissions. Published by BMJ.

Entities:  

Keywords:  cornea; drugs; glaucoma

Year:  2020        PMID: 32269062     DOI: 10.1136/bjophthalmol-2019-315776

Source DB:  PubMed          Journal:  Br J Ophthalmol        ISSN: 0007-1161            Impact factor:   4.638


  1 in total

1.  Long-Term Intraocular Pressure-Lowering Effects and Adverse Events of Ripasudil in Patients with Glaucoma or Ocular Hypertension over 24 Months.

Authors:  Hidenobu Tanihara; Takahiko Kakuda; Tetsuro Sano; Takashi Kanno; Yuji Kurihara
Journal:  Adv Ther       Date:  2022-02-12       Impact factor: 3.845

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.